Document Detail


Hydroxychloroquine use is associated with lower odds of persistently positive antiphospholipid antibodies and/or lupus anticoagulant in systemic lupus erythematosus.
MedLine Citation:
PMID:  22859353     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: Antiphospholipid antibodies (aPL) play an active role in the pathogenesis of the antiphospholipid syndrome (APS). Primary prevention in APS may be aimed at decreasing existing elevated aPL levels, or preventing high aPL titers and/or lupus anticoagulant (LAC) from developing in the first place. Hydroxychloroquine (HCQ) has been shown in retrospective studies to decrease aPL titers in laboratory studies, and to decrease thrombosis risk in patients with systemic lupus erythematosus (SLE). We investigated an association between HCQ use and persistent aPL and/or LAC in SLE.
METHODS: We identified all patients over 21 years old with SLE from an urban tertiary care center who had aPL and LAC measured on at least 2 occasions at least 12 weeks apart. We defined the presence of persistent LAC+ and/or at least 1 aPL ≥ 40 U [immunoglobulin A (IgA), IgG, or IgM] as the main outcome variable.
RESULTS: Among 90 patients included in the study, 17 (19%) had persistent LAC+ and/or at least 1 aPL ≥ 40 U. HCQ use was associated with significantly lower odds of having persistent LAC+ and/or aPL ≥ 40 U (OR 0.21, 95% CI 0.05, 0.79, p = 0.02), adjusted for age, ethnicity, and sex.
CONCLUSION: This is the first study to show that HCQ use is associated with lower odds of having persistently positive LAC and/or aPL. Data from this study provide a basis for the design of future prospective studies investigating the role of HCQ in primary and secondary prevention of APS.
Authors:
Anna Broder; Chaim Putterman
Related Documents :
6778453 - N-acetyl-beta-glucosaminidase, beta-glucuronidase and beta-galactosidase in the leukocy...
18595223 - Evaluation of the bard bta-test in the diagnosis of upper urinary tract tumours.
23885403 - Interleukin-18 promoter polymorphisms in egyptian patients with rheumatoid arthritis.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2012-08-01
Journal Detail:
Title:  The Journal of rheumatology     Volume:  40     ISSN:  0315-162X     ISO Abbreviation:  J. Rheumatol.     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-01-02     Completed Date:  2013-07-03     Revised Date:  2013-09-16    
Medline Journal Info:
Nlm Unique ID:  7501984     Medline TA:  J Rheumatol     Country:  Canada    
Other Details:
Languages:  eng     Pagination:  30-3     Citation Subset:  IM    
Affiliation:
Division of Rheumatology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York 10461, USA. abroder@montefiore.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Antibodies, Antiphospholipid / blood,  immunology*
Antiphospholipid Syndrome / complications,  immunology*
Antirheumatic Agents / therapeutic use*
Female
Humans
Hydroxychloroquine / therapeutic use*
Lupus Coagulation Inhibitor / blood,  immunology
Lupus Erythematosus, Systemic / complications,  drug therapy,  immunology*
Male
Middle Aged
Retrospective Studies
Grant Support
ID/Acronym/Agency:
DK090319/DK/NIDDK NIH HHS; R01 AR048692/AR/NIAMS NIH HHS; R01AR048692/AR/NIAMS NIH HHS
Chemical
Reg. No./Substance:
0/Antibodies, Antiphospholipid; 0/Antirheumatic Agents; 0/Lupus Coagulation Inhibitor; 118-42-3/Hydroxychloroquine
Comments/Corrections
Comment In:
J Rheumatol. 2013 Jan;40(1):9-15   [PMID:  23204219 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Blau arteritis resembling Takayasu disease with a novel NOD2 mutation.
Next Document:  Disease-modifying antirheumatic drug use in the treatment of juvenile idiopathic arthritis: a cross-...